{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptom relief, as it does not improve perinatal outcomes.  \n   Reason: Guideline states \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\"  \n\n2. **Different management plan** - Adjust delivery timing based on peak bile acid levels (consider earlier delivery only if ≥100 µmol/L).  \n   Reason: Guideline recommends \"planned early birth... to reduce the risk of adverse outcomes\" but specifies risk increases significantly at ≥100 µmol/L.  \n\n3. **Improved patient advice** - Clarify that CTG and ultrasound do not predict or prevent stillbirth in ICP; emphasize fetal movement monitoring instead.  \n   Reason: Guideline states \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\"  \n\n### Somewhat Important Recommendations\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods if available, as this helps interpret subsequent results.  \n   Reason: Guideline recommends baseline measurements in subsequent pregnancies to establish normal levels.  \n\n2. **Improved patient advice** - Discuss increased risks of pre-eclampsia/gestational diabetes and need for monitoring.  \n   Reason: Guideline notes women with ICP have higher chance of these conditions and should be monitored regularly.  \n\n3. **Different management plan** - Only perform additional investigations (e.g., clotting screen) if severe symptoms/comorbidities exist.  \n   Reason: Guideline states \"Additional investigations not recommended unless itch is severe or associated with comorbidities.\"  \n\n### Less Important Recommendations\n1. **Additional information needed** - Consider documenting hepatitis C status if not already known, though routine testing is no longer recommended.  \n   Reason: Guideline notes routine hepatitis C testing is not recommended but could be considered individually.  \n\n2. **Improved patient advice** - Provide links to ICP Support/RCOG resources for patient education.  \n   Reason: Guideline lists these as useful resources for women and families.  \n\n### Unimportant Recommendations\n1. **Additional information needed** - Consider more detailed social history regarding family support postpartum, though not directly relevant to ICP management.  \n   Reason: While not ICP-specific, may help with overall care planning.  \n\nKey areas where the note aligns well with guidelines:\n- Suspicion of ICP based on characteristic pruritus without rash  \n- Plans for bile acid/LFT monitoring  \n- Counseling about stillbirth risks in twins  \n\nThe most critical deviations are the routine use of UDCA and over-reliance on CTG/ultrasound for fetal monitoring. The guideline strongly emphasizes that these do not improve outcomes, and management should focus on bile acid levels and symptom control.\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 53 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 3293,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptom relief if needed, not for perinatal outcomes.\",\n      \"context\": \"Guideline states UDCA should not be routinely offered for adverse perinatal outcomes in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Aim for delivery at 36–37 weeks if bile acids <100 µmol/L. Consider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\",\n      \"suggestedText\": \"Plan delivery timing based strictly on peak bile acid levels: earlier delivery only if ≥100 µmol/L.\",\n      \"context\": \"Guideline specifies risk increases significantly at ≥100 µmol/L for delivery timing decisions\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Emphasize fetal movement monitoring over CTG/ultrasound as primary surveillance method.\",\n      \"context\": \"Guideline states CTG/ultrasound do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods if available\",\n      \"context\": \"Guideline recommends baseline measurements to help interpret subsequent results\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Gap: no discussion of pre-eclampsia/gestational diabetes risks\",\n      \"suggestedText\": \"Discuss increased risks of pre-eclampsia/gestational diabetes and need for monitoring\",\n      \"context\": \"Guideline notes women with ICP have higher chance of these conditions\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Full blood count and clotting screen (due to potential risk of coagulopathy).\",\n      \"suggestedText\": \"Only perform additional investigations (e.g., clotting screen) if severe symptoms/comorbidities exist\",\n      \"context\": \"Guideline states these are not recommended unless itch is severe or with comorbidities\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Gap: no patient education resources provided\",\n      \"suggestedText\": \"Provide links to ICP Support/RCOG resources for patient education\",\n      \"context\": \"Guideline lists these as useful resources for women and families\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-13T20-30-17",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptom relief, as it does not improve perinatal outcomes.  \\n   Reason: Guideline states \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\\\"  \\n\\n2. **Different management plan** - Adjust delivery timing based on peak bile acid levels (consider earlier delivery only if ≥100 µmol/L).  \\n   Reason: Guideline recommends \\\"planned early birth... to reduce the risk of adverse outcomes\\\" but specifies risk increases significantly at ≥100 µmol/L.  \\n\\n3. **Improved patient advice** - Clarify that CTG and ultrasound do not predict or prevent stillbirth in ICP; emphasize fetal movement monitoring instead.  \\n   Reason: Guideline states \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP, so monitoring fetal movements is advised.\\\"  \\n\\n### Somewhat Important Recommendations\\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods if available, as this helps interpret subsequent results.  \\n   Reason: Guideline recommends baseline measurements in subsequent pregnancies to establish normal levels.  \\n\\n2. **Improved patient advice** - Discuss increased risks of pre-eclampsia/gestational diabetes and need for monitoring.  \\n   Reason: Guideline notes women with ICP have higher chance of these conditions and should be monitored regularly.  \\n\\n3. **Different management plan** - Only perform additional investigations (e.g., clotting screen) if severe symptoms/comorbidities exist.  \\n   Reason: Guideline states \\\"Additional investigations not recommended unless itch is severe or associated with comorbidities.\\\"  \\n\\n### Less Important Recommendations\\n1. **Additional information needed** - Consider documenting hepatitis C status if not already known, though routine testing is no longer recommended.  \\n   Reason: Guideline notes routine hepatitis C testing is not recommended but could be considered individually.  \\n\\n2. **Improved patient advice** - Provide links to ICP Support/RCOG resources for patient education.  \\n   Reason: Guideline lists these as useful resources for women and families.  \\n\\n### Unimportant Recommendations\\n1. **Additional information needed** - Consider more detailed social history regarding family support postpartum, though not directly relevant to ICP management.  \\n   Reason: While not ICP-specific, may help with overall care planning.  \\n\\nKey areas where the note aligns well with guidelines:\\n- Suspicion of ICP based on characteristic pruritus without rash  \\n- Plans for bile acid/LFT monitoring  \\n- Counseling about stillbirth risks in twins  \\n\\nThe most critical deviations are the routine use of UDCA and over-reliance on CTG/ultrasound for fetal monitoring. The guideline strongly emphasizes that these do not improve outcomes, and management should focus on bile acid levels and symptom control.\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 53 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 3293,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptom relief if needed, not for perinatal outcomes.\",\n      \"context\": \"Guideline states UDCA should not be routinely offered for adverse perinatal outcomes in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Aim for delivery at 36–37 weeks if bile acids <100 µmol/L. Consider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\",\n      \"suggestedText\": \"Plan delivery timing based strictly on peak bile acid levels: earlier delivery only if ≥100 µmol/L.\",\n      \"context\": \"Guideline specifies risk increases significantly at ≥100 µmol/L for delivery timing decisions\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Emphasize fetal movement monitoring over CTG/ultrasound as primary surveillance method.\",\n      \"context\": \"Guideline states CTG/ultrasound do not predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods if available\",\n      \"context\": \"Guideline recommends baseline measurements to help interpret subsequent results\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Gap: no discussion of pre-eclampsia/gestational diabetes risks\",\n      \"suggestedText\": \"Discuss increased risks of pre-eclampsia/gestational diabetes and need for monitoring\",\n      \"context\": \"Guideline notes women with ICP have higher chance of these conditions\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Full blood count and clotting screen (due to potential risk of coagulopathy).\",\n      \"suggestedText\": \"Only perform additional investigations (e.g., clotting screen) if severe symptoms/comorbidities exist\",\n      \"context\": \"Guideline states these are not recommended unless itch is severe or with comorbidities\",\n      \"category\": \"modification\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Gap: no patient education resources provided\",\n      \"suggestedText\": \"Provide links to ICP Support/RCOG resources for patient education\",\n      \"context\": \"Guideline lists these as useful resources for women and families\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 1823\nCompletion tokens: 820\nTotal tokens: 2643\nEstimated cost: $0.001321",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1823,
    "completion_tokens": 820,
    "total_tokens": 2643,
    "estimated_cost_usd": 0.0013215
  }
}